ABCT Participant Directory

DeMay Bio is developing a biologic drug for Rheumatoid Arthritis that leverages a natural human protein to target a novel, but validated, disease mechanism directly in the joints. The new drug is an adjunct therapy, to be used alongside a patient’s immunosuppressant regimen,  to achieve better disease control, and to reduce disabling joint pain, tissue damage and mobility loss.